Advertisement

Adaptive Randomization for Master Protocols in Precision Medicine

  • Jianchang LinEmail author
  • Li An LinEmail author
  • Veronica Bunn
  • Rachael Liu
Chapter
Part of the ICSA Book Series in Statistics book series (ICSABSS)

Abstract

In the era of precision medicine and with the release of FDA draft guidance (2010), innovative adaptive designs, e.g. Umbrella (or Platform), Basket trials, adaptive enrichment strategies have generated greater interests and applications in clinical trials and resulted in rapidly revolutionized methodologies, including adaptive randomization, to conduct clinical trials in the setting of biomarkers and targeted therapies, whereas the traditional paradigm of treating very large number of unselected patients is increasingly less efficient, lacks cost effectiveness and is ethically challenging. In this paper, we presented a general overview of adaptive design and master protocols strategies for clinical trials, including Bayesian and frequentist approaches. Examples were used to demonstrate the procedure for design parameters calibration and operating characteristics. In addition, for clinical trials with survival outcomes, we also introduced a nonparametric model which is robust to model of event time distribution to response-adaptive design. The operating characteristics of the proposed design and the parametric design were compared by simulation studies, including their robustness properties with respect to model misspecifications. Both advantages and disadvantages of adaptive randomization were discussed in the summary from practical perspective of clinical trials as well as illustrations by master protocol case studies.

Keywords

Adaptive design Master protocol Precision medicine Adaptive randomization Clinical trials Survival analysis 

References

  1. Barker, A., Sigman, C.C., Kelloff, G.J., Hylton, N.M., Berry, D.A., Esserman, L.J.: I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin. Pharmacol. Ther. 86(1), 97–100 (2009)CrossRefGoogle Scholar
  2. Berry, S.M., Carlin, B.P., Lee, J.J., Muller, P.: Bayesian Adaptive Methods for Clinical Trials. CRC Press, Boca Raton (2010)CrossRefGoogle Scholar
  3. Case, L.D., Morgan, T.M.: Design of phase II cancer trials evaluating survival probabilities. BMC Med. Res. Methodol. 3(1), 6 (2003)CrossRefGoogle Scholar
  4. Cheung, Y.K., Chappell, R.: Sequential designs for phase I clinical trials with late-onset toxicities. Biometrics. 56(4), 1177–1182 (2000)MathSciNetCrossRefGoogle Scholar
  5. Cheung, Y.K., Thall, P.F.: Monitoring the rates of composite events with censored data in phase II clinical trials. Biometrics. 58(1), 89–97 (2002)MathSciNetCrossRefGoogle Scholar
  6. Hu, F., Rosenberger, W.F.: Introduction. In: The Theory of Response-Adaptive Randomization in Clinical Trials. Wiley, Hoboken, NJ (2006)CrossRefGoogle Scholar
  7. Huang, X., Ning, J., Li, Y., Estey, E., Issa, J.P., Berry, D.A.: Using short-term response information to facilitate adaptive randomization for survival clinical trials. Stat. Med. 28(12), 1680–1689 (2009)MathSciNetCrossRefGoogle Scholar
  8. Ji, Y., Bekele, B.N.: Adaptive randomization for multi-arm comparative clinical trials based on joint efficacy/toxicity outcomes. Biometrics. 65(3), 876–884 (2009)MathSciNetCrossRefGoogle Scholar
  9. Kairalla, J.A., Coffey, C.S., Thomann, M.A., Muller, K.E.: Adaptive trial designs: A review of barriers and opportunities. Trials. 13(1), 145 (2012)CrossRefGoogle Scholar
  10. Lin, J., Bunn, V.: Comparison of multi-arm multi-stage design and adaptive randomization in platform clinical trials. Contemp. Clin. Trials. 54, 48–59 (2017)CrossRefGoogle Scholar
  11. Lin, J., Lin, L., Sankoh, S.: A general overview of adaptive randomization design for clinical trials. J. Biom. Biostat. 7, 294 (2016a)Google Scholar
  12. Lin, J., Lin, L., Sankoh, S.: A Bayesian response-adaptive covariate-adjusted randomization design for clinical trials. J. Biom. Biostat. 7, 287 (2016b)Google Scholar
  13. Lin, J., Lin, L., Sankoh, S.: A phase II trial design with Bayesian adaptive covariate-adjusted randomization. In: Statistical Applications from Clinical Trials and Personalized Medicine to Finance and Business Analytics, ICSA Book Series in Statistics, pp. 61–73. Springer, Cham (2016c)CrossRefGoogle Scholar
  14. Menis, J., Hasan, B., Besse, B.: New clinical research strategies in thoracic oncology: clinical trial design, adaptive, basket and umbrella trials, new end-points and new evaluations of response. Eur. Respir. Rev. 23, 367–378 (2014)CrossRefGoogle Scholar
  15. Ning, J., Huang, X.: Response-adaptive randomization for clinical trials with adjustment for covariate imbalance. Stat. Med. 29(17), 1761–1768 (2010)MathSciNetCrossRefGoogle Scholar
  16. Renfro, L.A., Mallick, H., An, M.-W., Sargent, D.J., Mandrekar, S.J.: Clinical trial designs incorporating predictive biomarkers. Cancer Treat. Rev. 43, 74–82 (2016).  https://doi.org/10.1016/j.ctrv.2015.12.008 CrossRefGoogle Scholar
  17. Rosenberger, W.F., Sverdlov, O., Hu, F.: Adaptive randomization for clinical trials. J. Biopharm. Stat. 22(4), 719–736 (2012)MathSciNetCrossRefGoogle Scholar
  18. Thall, P.F., Wathen, J.K.: Practical Bayesian adaptive randomisation in clinical trials. Eur. J. Cancer. 43(5), 859–866 (2007)CrossRefGoogle Scholar
  19. U.S. Food and Drug Administration. Guidance for industry: Adaptive design clinical trials for drugs and biologics. Draft guidance (2010)Google Scholar
  20. Woodcock, J., LaVange, L.: Master protocols to study multiple therapies, multiple diseases, or both. N. Engl. J. Med. 377, 62–70 (2017)CrossRefGoogle Scholar
  21. Yin, G.: Clinical Trial Design: Bayesian and Frequentist Adaptive Methods, vol. 876. Wiley, Hoboken (2013)Google Scholar
  22. Yin, G., Chen, N., Jack Lee, J.: Phase II trial design with Bayesian adaptive randomization and predictive probability. J. R. Stat. Soc.: Ser. C: Appl. Stat. 61(2), 219–235 (2012)MathSciNetCrossRefGoogle Scholar
  23. Yuan, Y., Huang, X., Liu, S.: A Bayesian response-adaptive covariate-balanced randomization design with application to a leukemia clinical trial. Stat. Med. 30(11), 1218–1229 (2011)MathSciNetCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Takeda PharmaceuticalsCambridgeUSA
  2. 2.Merck & Co., Inc.RahwayUSA

Personalised recommendations